Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Evaluate the CNS-Penetrant EGFR/ERBB1 Inhibitor ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)

NCT05222802 is registered in ClinicalTrials.gov with Katmai Pharmaceuticals Inc. as lead sponsor.

NCT NCT05222802
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05222802 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Evaluate the CNS-Penetrant EGFR/ERBB1 Inhibitor ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)
Lead sponsor
Katmai Pharmaceuticals Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
February 25, 2022
Completion date
September 30, 2025
Enrollment
52 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme